- You are here:
- Home »
- Blog »
- integrative therapy »
- Renal Cell Carcinoma-Resveratrol
Renal Cell Carcinoma-Resveratrol
“Resveratrol potentiated sorafenib induced inhibitory effect on constitutive STAT3 and STAT5 phosphorylation, apoptotic effects in 786-O cells, and this correlated with down-regulation of various oncogenic gene products.”
Sorafenib is an angiogenesis inhibitor that is an FDA-approved chemotherapy shown to kill renal cell carcinoma aka kidney cancer. Resveratrol, according to the same Wikipedia entry, is also an angiogenesis inhibitor.
According to the study linked and excerpted below, Resveratrol “potentiates sorafenib-induced apoptosis in renal cell carcinoma.” (I’m not an oncologist, but I’m pretty sure that means resveratrol enhances sorafenib in kidney cancer).
The bottom line for kidney cancer patients and survivors is that when combined, sorafenib and resveratrol are a kidney cancer double-whammy.
I am both a cancer survivor and a cancer coach. Years of living with an “incurable cancer” coupled with research have taught me that complicated, aggressive cancers like kidney cancer require the best of both conventional and non-conventional therapies. Sorafenib is a conventional kidney cancer therapy and resveratrol is an evidence-based non-conventional kidney cancer therapy. Together, they are a powerful weapon for kidney cancer patients.
Resveratrol has also been shown to kill my cancer multiple myeloma. I have been supplementing with Life Extension Optimized Resveratrol for years.
Have you been diagnosed with renal cell carcinoma? What stage? Please scroll down the page, post a question or comment and I will reply to you ASAP.
Thank you,
David Emerson
- Cancer Survivor
- Cancer Coach
- Director PeopleBeatingCancer
Recommended Reading:
- Ken Youner, kidney cancer survivor
- Kidney Cancer Complementary Therapy-Vitamin D
- Stage IV Renal Cell Cancer- IV Alpha Lipoid Acid, Low-Dose Naltrexone
Angiogenesis inhibitor
“An angiogenesis inhibitor is a substance that inhibits the growth of new blood vessels (angiogenesis). Some angiogenesis inhibitors are endogenous and a normal part of the body’s control and others are obtained exogenously through pharmaceutical drugs or diet…”
Resveratrol promotes regression of renal carcinoma cells via a renin-angiotensin system suppression-dependent mechanism
Abstract
The aim of the present study was to investigate the effect of resveratrol on renal carcinoma cells and explore possible renin-angiotensin system-associated mechanisms.
After resveratrol treatment, the cell viability, apoptosis rate, cytotoxicity levels, caspase 3/7 activity and the levels of angiotensin II (AngII), AngII type 1 receptor (AT1R), vascular endothelial growth factor (VEGF) and cyclooxygenase-2 (COX-2) were evaluated in renal carcinoma cells.
The effects of AngII, AT1R, VEGF and COX-2 on resveratrol-induced cell growth inhibition and apoptosis were also examined. The results indicated that resveratrol treatment may suppress growth, induce apoptosis, and decrease AngII, AT1R, VEGF and COX-2 levels in renal carcinoma ACHN and A498 cells. In addition, resveratrol-induced cell growth suppression and apoptosis were reversed when co-culturing with AT1R or VEGF. Thus, resveratrol may suppress renal carcinoma cell proliferation and induce apoptosis via an AT1R/VEGF pathway.
Resveratrol attenuates constitutive STAT3 and STAT5 activation through induction of PTPε and SHP-2 tyrosine phosphatases and potentiates sorafenib-induced apoptosis in renal cell carcinoma
“We investigated the effect of resveratrol (RES), an edible polyphenol phytoalexin on STAT3 and STAT5 activation cascade in both Caki-1 and 786-O RCC cell lines…
We also found that RES downregulated the expression of STAT3/5-regulated antiapoptotic, proliferative, and metastatic gene products; and this correlated with induction of caspase-3 activation and anti-invasive activity. Beside, RES potentiated sorafenib induced inhibitory effect on constitutive STAT3 and STAT5 phosphorylation, apoptotic effects in 786-O cells, and this correlated with down-regulation of various oncogenic gene products…”